Fighting viruses with antibiotics: an overlooked path

International Journal of Antimicrobial Agents

Volumn 48, Issue 4, 2016, Pages 349-352

  Colson, Philippe ^a,b   Raoult, Didier ^a,b  

^a TIMONE HOSPITAL   (France)

^b AIX MARSEILLE UNIVERSITÉ   (France)

Author keywords

Antibiotic; Antimicrobial; Antiviral; Drug repurposing; Virus

Indexed keywords

ABAMECTIN; ANTIBIOTIC AGENT; DALBAVANCIN; HEPACIVIRIN; IVERMECTIN; ORITAVANCIN; TEICOPLANIN; TELAVANCIN; ANTIINFECTIVE AGENT;

ANTIVIRAL ACTIVITY; CHIKUNGUNYA VIRUS; DRUG APPROVAL; EBOLAVIRUS; EDITORIAL; ENZYME INHIBITION; FOOD AND DRUG ADMINISTRATION; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN RESPIRATORY SYNCYTIAL VIRUS; INFLUENZA VIRUS; MICROBIAL DIVERSITY; NONHUMAN; PRIORITY JOURNAL; RNA SYNTHESIS; SEMLIKI FOREST VIRUS; SINDBIS VIRUS; VIRUS ENTRY; VIRUS LIKE AGENT; VIRUS REPLICATION; YELLOW FEVER VIRUS; DRUG EFFECTS; DRUG REPOSITIONING; HUMAN; VIROLOGY; VIRUS; VIRUS DISEASES;

ANTI-BACTERIAL AGENTS; DRUG REPOSITIONING; HUMANS; VIRUS DISEASES; VIRUSES;

EID: 84988452206     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2016.07.004     Document Type: Editorial

References (46)

1. [1] Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380 (2012), 2095–2128.
2. [2] Morens, D.M., Fauci, A.S., Emerging infectious diseases: threats to human health and global stability. PLoS Pathog, 9, 2013 e1003467.
3. [3] Zumla, A., Chan, J.F., Azhar, E.I., Hui, D.S., Yuen, K.Y., Coronaviruses—drug discovery and therapeutic options. Nat Rev Drug Discov 15 (2016), 327–347.
4. [4] Bekerman, E., Einav, S., Infectious disease. Combating emerging viral threats. Science 348 (2015), 282–283.
5. [5] Katlama, C., Costagliola, D., Autran, B., Tackling latency as a barrier to an HIV cure: what next?. Lancet HIV 2 (2015), e504–5.
6. [6] Zeisel, M.B., Lucifora, J., Mason, W.S., Sureau, C., Beck, J., Levrero, M., et al. Towards an HBV cure: state-of-the-art and unresolved questions—report of the ANRS Workshop on HBV cure. Gut 64 (2015), 1314–1326.
7. [7] Antonelli, G., Turriziani, O., Antiviral therapy: old and current issues. Int J Antimicrob Agents 40 (2012), 95–102.
8. [8] Churchill, M.J., Deeks, S.G., Margolis, D.M., Siliciano, R.F., Swanstrom, R., HIV reservoirs: what, where and how to target them. Nat Rev Microbiol 14 (2016), 55–60.
9. [9] De Clercq, E., Looking back in 2009 at the dawning of antiviral therapy now 50 years ago: an historical perspective. Adv Virus Res 73 (2009), 1–53.
10. [10] Geddes, A., 80th anniversary of the discovery of penicillin: an appreciation of Sir Alexander Fleming. Int J Antimicrob Agents, 32, 2008, 373.
11. [11] Aminov, R.I., A brief history of the antibiotic era: lessons learned and challenges for the future. Front Microbiol, 1, 2010, 134.
12. [12] Lwoff, A., The concept of virus. J Gen Microbiol 17 (1957), 239–253.
13. [13] Wilkinson, L., The development of the virus concept as reflected in corpora of studies on individual pathogens. 1. Beginnings at the turn of the century. Med Hist 18 (1974), 211–221.
14. [14] Sharma, V., Colson, P., Pontarotti, P., Raoult, D., Mimivirus inaugurated in the 21st century: the beginning of a reclassification of viruses. Curr Opin Microbiol 31 (2016), 16–24.
15. [15] Wang, Y., Cui, R., Li, G., Gao, Q., Yuan, S., Altmeyer, R., et al. Teicoplanin inhibits Ebola pseudovirus infection in cell culture. Antiviral Res 125 (2016), 1–7.
16. [16] Zhou, N., Pan, T., Zhang, J., Li, Q., Zhang, X., Bai, C., et al. Glycopeptide antibiotics potently inhibit cathepsin L in the late endosome/lysosome and block the entry of Ebola virus, Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV). J Biol Chem 291 (2016), 9218–9232.
17. [17] Varghese, F.S., Kaukinen, P., Glasker, S., Bespalov, M., Hanski, L., Wennerberg, K., et al. Discovery of berberine, abamectin and ivermectin as antivirals against chikungunya and other alphaviruses. Antiviral Res 126 (2016), 117–124.
18. [18] De Burghgraeve, T., Kaptein, S.J., Ayala-Nunez, N.V., Mondotte, J.A., Pastorino, B., Printsevskaya, S.S., et al. An analogue of the antibiotic teicoplanin prevents Flavivirus entry in vitro. PLoS ONE, 7, 2012 e37244.
19. [19] Balzarini, J., Keyaerts, E., Vijgen, L., Egberink, H., De Clercq, E., Van Ranst, M., et al. Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics. Antiviral Res 72 (2006), 20–33.
20. [20] Bereczki, I., Mandi, A., Roth, E., Borbas, A., Fizil, A., Komaromi, I., et al. A few atoms make the difference: synthetic, CD, NMR and computational studies on antiviral and antibacterial activities of glycopeptide antibiotic aglycon derivatives. Eur J Med Chem 94 (2015), 73–86.
21. [21] Bereczki, I., Kicsak, M., Dobray, L., Borbas, A., Batta, G., Keki, S., et al. Semisynthetic teicoplanin derivatives as new influenza virus binding inhibitors: synthesis and antiviral studies. Bioorg Med Chem Lett 24 (2014), 3251–3254.
22. [22] Sipos, A., Torok, Z., Roth, E., Kiss-Szikszai, A., Batta, G., Bereczki, I., et al. Synthesis of isoindole and benzoisoindole derivatives of teicoplanin pseudoaglycon with remarkable antibacterial and antiviral activities. Bioorg Med Chem Lett 22 (2012), 7092–7096.
23. [23] Preobrazhenskaya, M.N., Olsufyeva, EN., Polycyclic peptide and glycopeptide antibiotics and their derivatives as inhibitors of HIV entry. Antiviral Res 71 (2006), 227–236.
24. [24] Balzarini, J., Pannecouque, C., De Clercq, E., Pavlov, A.Y., Printsevskaya, S.S., Miroshnikova, O.V., et al. Antiretroviral activity of semisynthetic derivatives of glycopeptide antibiotics. J Med Chem 46 (2003), 2755–2764.
25. [25] Maieron, A., Kerschner, H., Teicoplanin therapy leading to a significant decrease in viral load in a patient with chronic hepatitis C. J Antimicrob Chemother 67 (2012), 2537–2538.
26. [26] Obeid, S., Printsevskaya, S.S., Olsufyeva, E.N., Dallmeier, K., Durantel, D., Zoulim, F., et al. Inhibition of hepatitis C virus replication by semi-synthetic derivatives of glycopeptide antibiotics. J Antimicrob Chemother 66 (2011), 1287–1294.
27. [27] Mastrangelo, E., Pezzullo, M., De Burghgraeve, T., Kaptein, S., Pastorino, B., Dallmeier, K., et al. Ivermectin is a potent inhibitor of Flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug. J Antimicrob Chemother 67 (2012), 1884–1894.
28. [28] Lee, Y.J., Lee, C., Ivermectin inhibits porcine reproductive and respiratory syndrome virus in cultured porcine alveolar macrophages. Arch Virol 161 (2016), 257–268.
29. [29] Reeves, W.K., Nol, P., Miller, M.M., Jones, G.Z., Effects of ivermectin on the susceptibility of Culicoides sonorensis (Diptera: Ceratopogonidae) to bluetongue and epizootic hemorrhagic disease viruses. J Vector Ecol 34 (2009), 161–163.
30. [30] Owens, B., 2015 Nobel Prize goes to antiparasitic drug discoverers. Lancet, 386, 2015, 1433.
31. [31] Chen, K.X., Njoroge, F.G., Arasappan, A., Venkatraman, S., Vibulbhan, B., Yang, W., et al. Novel potent hepatitis C virus NS3 serine protease inhibitors derived from proline-based macrocycles. J Med Chem 49 (2006), 995–1005.
32. [32] Todorov, S.D., Wachsman, M., Tome, E., Dousset, X., Destro, M.T., Dicks, L.M., et al. Characterisation of an antiviral pediocin-like bacteriocin produced by Enterococcus faecium. Food Microbiol 27 (2010), 869–879.
33. [33] Suttle, C.A., Marine viruses—major players in the global ecosystem. Nat Rev Microbiol 5 (2007), 801–812.
34. [34] Rodriguez-Brito, B., Li, L., Wegley, L., Furlan, M., Angly, F., Breitbart, M., et al. Viral and microbial community dynamics in four aquatic environments. ISME J 4 (2010), 739–751.
35. [35] Cadwell, K., Expanding the role of the virome: commensalism in the gut. J Virol 89 (2015), 1951–1953.
36. [36] Díaz-Muñoz, S.L., Koskella, B., Bacteria–phage interactions in natural environments. Adv Appl Microbiol 89 (2014), 135–183.
37. [37] Lagier, J.C., Hugon, P., Khelaifia, S., Fournier, P.E., La Scola, B., Raoult, D., The rebirth of culture in microbiology through the example of culturomics to study human gut microbiota. Clin Microbiol Rev 28 (2015), 237–264.
38. [38] Hugon, P., Lagier, J.C., Colson, P., Bittar, F., Raoult, D., Repertoire of human gut microbes. Microb Pathog, 2016, 10.1016/j.micpath.2016.06.020.
39. [39] Fuhrman, J.A., Schwalbach, M., Viral influence on aquatic bacterial communities. Biol Bull 204 (2003), 192–195.
40. [40] Dalmasso, M., Hill, C., Ross, R.P., Exploiting gut bacteriophages for human health. Trends Microbiol 22 (2014), 399–405.
41. [41] Makarova, K.S., Wolf, Y.I., Alkhnbashi, O.S., Costa, F., Shah, S.A., Saunders, S.J., et al. An updated evolutionary classification of CRISPR-Cas systems. Nat Rev Microbiol 13 (2015), 722–736.
42. [42] Mullard, A., Drug repurposing programmes get lift off. Nat Rev Drug Discov 11 (2012), 505–506.
43. [43] Nair, P., Second act: drug repurposing gets a boost as academic researchers join the search for novel uses of existing drugs. Proc Natl Acad Sci USA 110 (2013), 2430–2432.
44. [44] De Clercq, E., Strategies in the design of antiviral drugs. Nat Rev Drug Discov 1 (2002), 13–25.
45. [45] Bisson, W.H., Drug repurposing in chemical genomics: can we learn from the past to improve the future?. Curr Top Med Chem 12 (2012), 1883–1888.
46. [46] Dyall, J., Coleman, C.M., Hart, B.J., Venkataraman, T., Holbrook, M.R., Kindrachuk, J., et al. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother 58 (2014), 4885–4893.